135 related articles for article (PubMed ID: 29569972)
1. Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma.
Zhang PP; Ding DZ; Shi B; Zhang SQ; Gu LL; Wang YC; Cheng C
Leuk Lymphoma; 2018 Nov; 59(11):2639-2649. PubMed ID: 29569972
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of TRIM28 inhibits growth and increases apoptosis of nude mice with non‑small cell lung cancer xenografts.
Liu L; Zhang L; Wang J; Zhao X; Xu Q; Lu Y; Zuo Y; Chen L; Du J; Lian Y; Zhang Q
Mol Med Rep; 2018 Jan; 17(1):835-842. PubMed ID: 29115614
[TBL] [Abstract][Full Text] [Related]
3. Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells.
Bhatti IA; Abhari BA; Fulda S
Cancer Lett; 2017 Oct; 405():63-72. PubMed ID: 28716527
[TBL] [Abstract][Full Text] [Related]
4. TRIM28 as an independent prognostic marker plays critical roles in glioma progression.
Qi ZX; Cai JJ; Chen LC; Yue Q; Gong Y; Yao Y; Mao Y
J Neurooncol; 2016 Jan; 126(1):19-26. PubMed ID: 26476730
[TBL] [Abstract][Full Text] [Related]
5. Steroid receptor coactivator-3 is a pivotal target of gambogic acid in B-cell Non-Hodgkin lymphoma and an inducer of histone H3 deacetylation.
Zhao Z; Zhang X; Wen L; Yi S; Hu J; Ruan J; Zhao F; Cui G; Fang J; Chen Y
Eur J Pharmacol; 2016 Oct; 789():46-59. PubMed ID: 27370960
[TBL] [Abstract][Full Text] [Related]
6. TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.
Li F; Wang Z; Lu G
Oncol Rep; 2018 Apr; 39(4):1860-1866. PubMed ID: 29393469
[TBL] [Abstract][Full Text] [Related]
7. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.
Czerwińska P; Shah PK; Tomczak K; Klimczak M; Mazurek S; Sozańska B; Biecek P; Korski K; Filas V; Mackiewicz A; Andersen JN; Wiznerowicz M
Oncotarget; 2017 Jan; 8(1):863-882. PubMed ID: 27845900
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial-mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/β-catenin signaling pathway.
Deng B; Zhang S; Zhang Y; Miao Y; Meng X; Guo K
Neoplasma; 2017; 64(6):893-900. PubMed ID: 28895414
[TBL] [Abstract][Full Text] [Related]
9. TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.
Liu L; Xiao L; Liang X; Chen L; Cheng L; Zhang L; Wu X; Xu Q; Ma C
Oncol Rep; 2017 Jun; 37(6):3597-3605. PubMed ID: 28498400
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
11. The complexity of TRIM28 contribution to cancer.
Czerwińska P; Mazurek S; Wiznerowicz M
J Biomed Sci; 2017 Aug; 24(1):63. PubMed ID: 28851455
[TBL] [Abstract][Full Text] [Related]
12. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
[TBL] [Abstract][Full Text] [Related]
13. TRIM28 regulates Igf2-H19 and Dlk1-Gtl2 imprinting by distinct mechanisms during sheep fibroblast proliferation.
Luo J; Zhang Y; Guo Y; Tang H; Wei H; Liu S; Wang X; Wang L; Zhou P
Gene; 2017 Dec; 637():152-160. PubMed ID: 28947302
[TBL] [Abstract][Full Text] [Related]
14. Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein.
Wei C; Cheng J; Zhou B; Zhu L; Khan MA; He T; Zhou S; He J; Lu X; Chen H; Zhang D; Zhao Y; Fu J
Sci Rep; 2016 Jul; 6():29822. PubMed ID: 27412325
[TBL] [Abstract][Full Text] [Related]
15. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
[TBL] [Abstract][Full Text] [Related]
17. [Expression of survivin and P63 protein in B cell non-Hodgkin's lymphoma and their effects on cell apoptosis and proliferation].
Zuo XL; Zhou Y; Zhou X; Liu XH; Zhang KJ; Yang HQ; Meng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):99-102. PubMed ID: 17490531
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
[TBL] [Abstract][Full Text] [Related]
19. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
Liu HL; Chen Y; Cui GH; Zhou JF
Acta Pharmacol Sin; 2005 May; 26(5):603-9. PubMed ID: 15842781
[TBL] [Abstract][Full Text] [Related]
20. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells.
Vega MI; Baritaki S; Huerta-Yepez S; Martinez-Paniagua MA; Bonavida B
Leuk Lymphoma; 2011 Jan; 52(1):108-21. PubMed ID: 21133714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
